Evidence mapPaperPMID 36498228Full record

Trial reportInternational journal of environmental research and public health2022

6-Week Supplementation with

Diego Fernández-Lázaro, Jesús Seco-Calvo, Jorge Pascual-Fernández, Carlos Domínguez-Ortega, Miguel Del Valle Soto, Juan Mielgo-Ayuso

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Sub-Acute Toxicity Evaluation and Antiurolithiatic Activity ofJournal of experimental pharmacology · 2026
    Article
  7. Article
  8. Article
  9. Observational
  10. 3 Biotech · 2025
    Article
  11. Article
  12. Nutrients · 2024
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Diego Fernández-LázaroDepartment of Cellular Biology, Genetics, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain.ORCID 0000-0002-6522-8896
Jesús Seco-CalvoPhysiotherapy Department, Institute of Biomedicine (IBIOMED), Campus of Vegazana, University of Leon, 24071 Leon, Spain.ORCID 0000-0002-7818-9777
Jorge Pascual-FernándezMedical Hospital Emergency Service of Hospital San Pedro, Rioja Health, 26006 Logroño, Spain.
Carlos Domínguez-OrtegaDepartment of Cellular Biology, Genetics, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain.
Miguel Del Valle SotoDepartment of Cellular Morphology and Biology, Universidad de Oviedo, 33006 Oviedo, Spain.
Juan Mielgo-AyusoDepartment of Health Sciences, Faculty of Health Sciences, University of Burgos, 09001 Burgos, Spain.ORCID 0000-0002-6554-4602
Universidad de Valladolid · ESHospital San Pedro · ESUniversidad de Burgos · ESUniversidad de Oviedo · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tribulus terrestris L. (TT) ingredients have anti-inflammatory and antioxidant activities, but their effects on exercise-induced muscle damage (EIMD) in trained athletes are uncertain. The purpose of this single-blind placebo-controlled trial, in accordance with CONSORT guidelines, was to examine the effect of 6 weeks of TT supplementation on muscle metabolism, inflammation biomarkers, and oxidant status. Thirty trained male CrossFit® athletes were randomly assigned to be supplemented with 770 mg/day of TT (intervention group (IG)) or receive a placebo daily (control group (CG)) for 6 weeks. Muscle damage enzymes, inflammation biomarkers, and Total Antioxidant Status (TAS) were assessed at baseline (T1), 21 days after baseline (T2), and after 42 days (T3). Grace, a Workout of the Day, was measured in T1 and T3. Statistical significance (p < 0.05) was found between IG and CG in Lactate Dehydrogenase (LDH), C-reactive protein (CRP), and TAS levels at the end of the follow-up. Furthermore, TAS levels were significantly (p < 0.05) lower at T2 and T3 relative to baseline in the IG, also LDH and CRP increased significantly (p < 0.05) at T2 and T3 relative to baseline in the CG. No significant (p > 0.05) decreases in muscle damage or inflammation biomarkers were observed, although a slight downward trend was observed after 6 weeks for supplemented athletes. TT supplementation could attenuate the CrossFit® training program-induced oxidative stress, muscle damage, and inflammation which could be due to the natural antioxidant and anti-inflammatory properties of TT.

Indexed as

Dietary SupplementsMusclesPlant PreparationsTribulusAnti-Inflammatory AgentsAntioxidantsAthletesBiomarkersHumansInflammationL-Lactate DehydrogenaseMaleOxidative StressSingle-Blind MethodAnti-Inflammatory AgentsAntioxidantsBiomarkersL-Lactate DehydrogenasePlant PreparationsCrossFit®exercise-induced oxidative stressherbal supplementationinflammation responsemuscle damageTribulus terrestris L.

Identifiers

PMID36498228
PMCPMC9736311
OpenAlexW4310676300

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.